The LEAD- company PledPharma has started a clinical phase II study. The first patient included in a clinical study in patients with acute myocardial infarction.

Earlier this autumn, PledPharma AB received approval from the Swedish Medical Products Agency (MPA; Läkemedelsverket) and the local Ethical Committee to start a clinical phase II trial in patients with Acute Myocardial Infarction (AMI). The first patient has now been included in the trial.

"The study may lead to a more effective reduction in infarct size during treatment with PCI, and thereby decrease the incidence and severity of secondary heart failure after AMI”, says Professor Per Jynge, Medical Director in PledPharma AB.

Read more about the news

Read more about PledPharma